Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.96	$1.70	$1.07 ▼ $6.18	$118.23M	1.19	1.09 million shs	2.18 million shs
ARAV Aravive	$0.04	$0.04	$0.04 ▼ $2.46	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$7.53	$7.93	$5.85 ▼ $24.17	$214.03M	2.36	350,850 shs	466,259 shs
CRVS Corvus Pharmaceuticals	$11.91	$13.73	$3.55 ▼ $26.95	$1.00B	0.84	1.33 million shs	1.98 million shs
HROW Harrow	$42.87	$36.56	$28.54 ▼ $54.85	$1.60B	0.28	746,301 shs	1.07 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	+11.36%	+23.27%	+8.29%	-38.17%
ARAV Aravive	0.00%	0.00%	0.00%	0.00%	0.00%
ARCT Arcturus Therapeutics	0.00%	+8.03%	+7.26%	+13.57%	-39.03%
CRVS Corvus Pharmaceuticals	0.00%	-0.17%	-8.94%	-10.65%	+203.05%
HROW Harrow	0.00%	+13.89%	+30.07%	+28.82%	+36.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALDX Aldeyra Therapeutics	$1.96	$1.70	$1.07 ▼ $6.18	$118.23M	1.19	1.09 million shs	2.18 million shs
ARAV Aravive	$0.04	$0.04	$0.04 ▼ $2.46	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$7.53	$7.93	$5.85 ▼ $24.17	$214.03M	2.36	350,850 shs	466,259 shs
CRVS Corvus Pharmaceuticals	$11.91	$13.73	$3.55 ▼ $26.95	$1.00B	0.84	1.33 million shs	1.98 million shs
HROW Harrow	$42.87	$36.56	$28.54 ▼ $54.85	$1.60B	0.28	746,301 shs	1.07 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALDX Aldeyra Therapeutics	0.00%	+11.36%	+23.27%	+8.29%	-38.17%
ARAV Aravive	0.00%	0.00%	0.00%	0.00%	0.00%
ARCT Arcturus Therapeutics	0.00%	+8.03%	+7.26%	+13.57%	-39.03%
CRVS Corvus Pharmaceuticals	0.00%	-0.17%	-8.94%	-10.65%	+203.05%
HROW Harrow	0.00%	+13.89%	+30.07%	+28.82%	+36.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALDX Aldeyra Therapeutics	2.00	Hold	$5.50	180.61% Upside
ARAV Aravive	0.00	N/A	N/A	N/A
ARCT Arcturus Therapeutics	2.67	Moderate Buy	$25.44	237.91% Upside
CRVS Corvus Pharmaceuticals	2.71	Moderate Buy	$33.33	179.88% Upside
HROW Harrow	2.64	Moderate Buy	$69.43	61.95% Upside

Current Analyst Ratings Breakdown

Latest ARCT, ALDX, CRVS, ARAV, and HROW Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2026	ALDX Aldeyra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/13/2026	HROW Harrow	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$91.00 ➝ $88.00
5/12/2026	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$63.00
4/29/2026	CRVS Corvus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
4/22/2026	HROW Harrow	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
4/21/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
4/17/2026	CRVS Corvus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$40.00
4/17/2026	CRVS Corvus Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$40.00
4/17/2026	HROW Harrow	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$63.00
4/7/2026	HROW Harrow	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$74.00 ➝ $65.00
4/3/2026	HROW Harrow	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	$0.74 per share	N/A
ARAV Aravive	N/A	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	$82.03M	2.61	N/A	N/A	$7.53 per share	1.00
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.13 per share	93.96	$0.73 per share	N/A
HROW Harrow	$272.30M	5.87	$0.86 per share	49.60	$1.41 per share	30.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALDX Aldeyra Therapeutics	-$33.85M	-$0.46	N/A	N/A	N/A	N/A	-57.34%	-36.33%	8/6/2026 (Estimated)
ARAV Aravive	N/A	-$0.90	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	-$65.78M	-$2.81	N/A	N/A	N/A	-143.80%	-36.55%	-28.40%	8/10/2026 (Estimated)
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.52	N/A	N/A	N/A	N/A	-38.92%	-35.75%	8/6/2026 (Estimated)
HROW Harrow	-$5.14M	-$0.41	N/A	19.85	N/A	-5.57%	19.59%	2.26%	8/10/2026 (Estimated)

Latest ARCT, ALDX, CRVS, ARAV, and HROW Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/11/2026	Q1 2026	HROW Harrow	-$0.43	-$0.74	-$0.31	-$0.74	$52.43 million	$44.20 million
5/8/2026	Q1 2026	ARCT Arcturus Therapeutics	-$1.0320	-$0.95	+$0.0820	-$0.95	$6.30 million	$2.06 million
5/7/2026	Q1 2026	ALDX Aldeyra Therapeutics	-$0.13	-$0.06	+$0.07	-$0.06	N/A	N/A
5/7/2026	Q1 2026	CRVS Corvus Pharmaceuticals	-$0.14	-$0.15	-$0.01	-$0.15	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALDX Aldeyra Therapeutics	N/A	N/A	N/A	N/A	N/A
ARAV Aravive	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HROW Harrow	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALDX Aldeyra Therapeutics	N/A	2.72	2.72
ARAV Aravive	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	6.31	6.31
CRVS Corvus Pharmaceuticals	N/A	19.81	19.81
HROW Harrow	10.30	2.48	2.30

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALDX Aldeyra Therapeutics	59.71%
ARAV Aravive	35.80%
ARCT Arcturus Therapeutics	94.54%
CRVS Corvus Pharmaceuticals	46.64%
HROW Harrow	72.76%

Insider Ownership

Company	Insider Ownership
ALDX Aldeyra Therapeutics	11.80%
ARAV Aravive	60.40%
ARCT Arcturus Therapeutics	17.80%
CRVS Corvus Pharmaceuticals	19.70%
HROW Harrow	12.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALDX Aldeyra Therapeutics	10	60.32 million	53.20 million	Optionable
ARAV Aravive	20	N/A	N/A	No Data
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
CRVS Corvus Pharmaceuticals	30	84.09 million	67.52 million	Optionable
HROW Harrow	180	37.28 million	32.50 million	Optionable

ARCT, ALDX, CRVS, ARAV, and HROW Headlines

Recent News About These Companies

Harrow (NASDAQ:HROW) & Hypermarcas (OTCMKTS:HYPMY) Critical Review

June 20 at 4:04 AM | americanbankingnews.com

Militia Capital Partners LP Takes Position in Harrow, Inc. $HROW

June 17, 2026 | marketbeat.com

Rice Hall James & Associates LLC Increases Stock Position in Harrow, Inc. $HROW

June 16, 2026 | marketbeat.com

Is Harrow, Inc. (HROW) A Good Stock To Buy Now?

June 13, 2026 | insidermonkey.com

Is Harrow, Inc. (HROW) A Good Stock To Buy Now?

June 13, 2026 | finance.yahoo.com

Can Harrow’s (HROW) VERKAZIA Relaunch Redefine Its Niche Ophthalmic Strategy?

June 12, 2026 | finance.yahoo.com

Harrow re-launches Verkazia to improve access for VKC treatment

June 11, 2026 | thepharmaletter.comT

HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US

June 11, 2026 | zacks.com

Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

June 10, 2026 | globenewswire.com

What Does Cantor Fitzgerald Think About Harrow (HROW) After Cutting Its Price Target?

June 5, 2026 | finance.yahoo.com

Harrow Health Releases June 2026 Investor Presentation Update

June 3, 2026 | tipranks.com

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

May 28, 2026 | finance.yahoo.com

Harrow to Present at William Blair's 46th Annual Growth Stock Conference

May 27, 2026 | globenewswire.com

Harrow, Inc. $HROW Stock Position Raised by Penn Capital Management Company LLC

May 27, 2026 | marketbeat.com

12th Street Asset Management Company LLC Makes New $4.47 Million Investment in Harrow, Inc. $HROW

May 26, 2026 | marketbeat.com

Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism

May 22, 2026 | finance.yahoo.com

Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism

May 20, 2026 | insidermonkey.com

Harrow: Demand Keeps It Interesting, Valuation Keeps It A Hold

May 20, 2026 | seekingalpha.com

Insider Buying: Harrow (NASDAQ:HROW) Director Purchases 1,000 Shares of Stock

May 20, 2026 | insidertrades.com

Harrow, Inc. 2026 Q1 - Results - Earnings Call Presentation

May 19, 2026 | seekingalpha.com

Insider Buying: Harrow (NASDAQ:HROW) CFO Buys 3,500 Shares of Stock

May 16, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, ALDX, CRVS, ARAV, and HROW Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

$1.96 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$1.92 -0.03 (-1.79%)

As of 06/18/2026 06:51 PM Eastern

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

Aravive NASDAQ:ARAV

$0.04 0.00 (0.00%)

As of 06/18/2026

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.

Arcturus Therapeutics NASDAQ:ARCT

$7.53 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$7.50 -0.03 (-0.41%)

As of 06/18/2026 06:54 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Corvus Pharmaceuticals NASDAQ:CRVS

$11.91 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$12.15 +0.24 (+2.01%)

As of 06/18/2026 06:34 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Harrow NASDAQ:HROW

$42.87 0.00 (0.00%)

Closing price 06/18/2026 04:00 PM Eastern

Extended Trading

$42.46 -0.41 (-0.96%)

As of 06/18/2026 07:59 PM Eastern

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, ALDX, CRVS, ARAV, and HROW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, ALDX, CRVS, ARAV, and HROW Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, ALDX, CRVS, ARAV, and HROW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, ALDX, CRVS, ARAV, and HROW Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Aravive NASDAQ:ARAV

Arcturus Therapeutics NASDAQ:ARCT

Corvus Pharmaceuticals NASDAQ:CRVS

Harrow NASDAQ:HROW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARCT, ALDX, CRVS, ARAV, and HROW Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARCT, ALDX, CRVS, ARAV, and HROW Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARCT, ALDX, CRVS, ARAV, and HROW Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARCT, ALDX, CRVS, ARAV, and HROW Company Descriptions

Aldeyra Therapeutics NASDAQ:ALDX

Aravive NASDAQ:ARAV

Arcturus Therapeutics NASDAQ:ARCT

Corvus Pharmaceuticals NASDAQ:CRVS

Harrow NASDAQ:HROW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools